Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.
Gils RoexMarijke TimmersKristien WoutersDiana Campillo-DavoDonovan FlumensWilfried SchroyensYiwei ChuZwi N BernemanEva LionFeifei LuoSébastien AnguillePublished in: Journal of hematology & oncology (2020)
Although considerable toxicity was observed, BCMA-targeted CAR-T-cell therapy is highly efficacious even in advanced multiple myeloma. Subgroup analysis confirmed the anticipated inter-study heterogeneity and identified potential factors contributing to safety and efficacy. The results of this meta-analysis may assist the future design of CAR-T-cell studies and lead to optimized BCMA CAR-T-cell products.